In the second part of the interview with HCPLIve, Peter Toth, MD, Director of Preventive Cardiology, CGH Medical Center, discussed the use of new lipid treatment agents and whether they will become primary or secondary agents in treatment.
“I think mostly they can all be used in combination with statins or ezetimibe or probably even with PCSK9 monoclonal,” Toth said. “But let’s say a patient has no intolerance to statins, then it gives you a whole new mechanical approach by which you will try to influence and reduce the burden of atherogenic lipoproteins in the serum.”
He noted that clinicians can now take advantage of alternative pathways to reduce LDL-C and serum pathways that were not once possible.
Furthermore, Toth spoke about the effects of the COVID-19 pandemic on cholesterol levels in patients currently being treated for various concomitant conditions.
He noted that people stopped taking the medication and did not visit the hospital during the cardiovascular event for fear of contracting COVID-19.
“We lost an average of a year and a half of life in the U.S. because of the COVID pandemic,” Toth said. “I am absolutely certain that not only has the trend of increasing cardiovascular mortality expanded, but I am sure it has jumped. We have a lot to learn, we will certainly have to come up with new ways to protect our patients from a future pandemic.”
Finally, Toth noticed complications in statin adherence, as more and more patients believe they do not tolerate statins.
“The last 10 years have seen a steady increase in cardiovascular mortality among both men and women,” Toth said. “Despite the fact that in the last 30 years it’s been an obvious declining trend. So we have these miracle cures, they’re being used inadequately, and false assumptions are often stopped.”
Check out the first part of the interview with Dr. Peter Toth here.